Obalon Therapeutics (OBLN) 5M Share Common Stock IPO at Midpoint of Expected Range

October 6, 2016 5:53 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Obalon Therapeutics, Inc. (Nasdaq: OBLN) announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on October 6, 2016 under the symbol “OBLN.” In addition, the underwriters have been granted a 30-day option to purchase up to an additional 750,000 shares of common stock.

*** Note: The company was recently looking for a pricing range of $14 - $16 per share.

UBS Investment Bank, Canaccord Genuity and Stifel are acting as joint book-running managers for the offering. BTIG is acting as a co-manager.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on October 5, 2016. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by telephone at (888) 827-7275; Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110 or by telephone at (617) 371-3900 or by e-mail at prospectus@canaccordgenuity.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, IPOs, Trader Talk

Related Entities

Stifel, UBS, Canaccord Genuity, IPO, BTIG

Add Your Comment